You are here:

Archived: ranolazine (Ranexa)


following a resubmission:

ranolazine (Ranexa®) is not recommended for use within NHS Scotland.

Indication under review: as add-on therapy for the symptomatic treatment of patients with
stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal
therapies (such as beta blockers and/or calcium antagonists).

When added to standard doses of antianginal drugs, ranolazine increased exercise duration at
trough drug levels compared with placebo after 12 weeks treatment. Although significant the
effect size was modest.

The manufacturer did not present a sufficiently robust economic analysis to gain acceptance
by SMC.

The licence holder has indicated their intention to resubmit.

Drug Details

Drug Name: ranolazine (Ranexa)
SMC Drug ID: 565/09
Manufacturer: A Menarini Pharmaceuticals UK Ltd
Indication: Stable angina pectoris
BNF Category:
Sub Category: 2.6 Nitrates calcium-channel blockers and other antianginal drugs
Submission Type: Resubmission
Status: Not Recommended
Date Advice Published: 13 December 2010

Current Advice

IRP 12 November 2012

Archived Advice

Resubmission 16 January 2012
Full submission 7 September 2009